Abstract: Diester tertiary amines and quats and their methods of synthesis are disclosed. Also disclosed are personal care compositions comprising the disclosed compounds.

Abstract: Disclosed is a cooling sensation agent composition or sensory stimulation agent composition which contains at least one of diester compounds of dicarboxylic acid represented by the formula (1) wherein A represents CH2 or CH?CH, n represents an integer of 0 to 4 when A is CH2, or 1 when A is CH?CH, B is an alcohol residue having 10 to 18 carbon atoms and containing a para-menthane skeleton, which may have a substituent, and C is an alcohol residue having 6 to 18 carbon atoms, which may have a substituent as well as a flavor or fragrance composition, a beverage, a food product, a perfume or cosmetic product, a toiletry product, daily utensil products or groceries, a fiber, a fiber product, clothes, clothing or a medicine, wherein the cooling sensation agent composition or the sensory stimulation agent composition is compounded.

Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

Abstract: Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance.

Abstract: A method for regulating hair growth is provided which comprises administering, to a subject in need thereof, dodecylcarbomoylmethyltrimethylammonium chloride and/or a compound of salt thereof selected from 2-dimethylamino-N-ethyl-acetamide, 2-dimethylamino-N-(2-{2-[2-(2-dimethylamino-acetylamino)-ethoxy]-ethoxy}-ethyl)-acetamide, 2-dimethylamino-N-[8-(2-dimethylamino-acetylamino)-octyl]-acetamide, 2-dimethylamino-N-[2-(2-{2-[2-(2-dimethylamino-acetylamino)-ethoxy]-ethoxy}-ethoxy)-ethyl]-acetamide, 2-dimethylamino-N-[12-(2-dimethylamino-acetylamino)-dodecyl]-acetamide, and 2-dimethylamino-N-[4-(2-dimethylamino-acetamino)-butyl]acetamide.

Abstract: Provided is a compound preparation including at least one selected from the group consisting of ?3 polyunsaturated fatty acids and pharmaceutically acceptable salts and esters thereof and at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation is in a form of a soft capsule having a capsule coating with a pH of 7.0 to 9.5. The compound preparation suppresses the decomposition of the statin compounds and/or the modification/insolubilization of the capsule coating. A medical use for the compound preparation, a method of manufacturing the compound preparation and a method of using the compound preparation are also provided.

Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Abstract: To provide a preventive or ameliorating agent for liver diseases associated with hepatopathy comprising an omega-9 unsaturated fatty acid as an active ingredient.

Abstract: Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).

Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

Abstract: Disclosed are creatine ?-alaninate, compositions and formulations containing same, and methods of use therefor.

Abstract: Therapeutically effective compositions and methods to inhibit dry eye as well as other conditions are provided. A therapeutically effective composition consists of at least one surfactant; a preservative with reduced immunogenicity relative to thimerosol; a complexing agent; and deionized, demineralized, ozonated water.

Abstract: The invention relates to novel quaternary ammonium compounds of the esterquat type, to a method for the production thereof, and to the use thereof in formulations.

Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.

Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

Abstract: A skin treatment composition that characteristically contains alkylene polyglycol dineopentanoate having a specific structure. The object is to provide a skin treatment composition that gives a refreshing sensation at the time of application and contains an oil component that is highly safe with low skin irritation. The skin treatment composition specifically contains diethyleneglycol dineopentanoate, triethyleneglycol dineopentanoate, tetraethyleneglycol dineopentanoate, dipropyleneglycol dineopentanoate, tripropyleneglycol dineopentanoate, etc. Dipropyleneglycol dineopentanoate and tripropyleneglycol dineopentanoate are particularly preferable in terms of the sensation at the time of application; they provide a skin treatment composition that is particularly superior in absorption into the skin and a sensation of permeation and highly safe.

Abstract: The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.

Abstract: A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.

Abstract: The present invention relates to a spray-pumpable composition for topical use on the skin comprising hydrophilic silicon dioxide, an emulsifier, at least one active ingredient and optionally one or more additives. The present invention further relates to a method for the preparation of a spray-pumpable composition for topical use on the skin and the use of hydrophilic silicon dioxide for the preparation of suspensions in emulsions, in particular oil-in-water emulsions.

Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.

Abstract: A nerve-regenerating agent comprising, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a constituent fatty acid.

Abstract: Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.

Abstract: The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion.

Abstract: The present invention relates to a process for the preparation of an ester in a reactor, a device, a process for the preparation of a thermoplastic composition comprising the ester prepared according to the invention, a process for the production of a shaped article comprising the ester according to the invention or the thermoplastic composition according to the invention, a process for the production of a packed product, a process for the production of an at least partly coated object, and uses of the esters according to the invention as an additive in various compositions.

Abstract: The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components.

Abstract: Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of —CH2—, —S—, and —O— or absent; wherein Y is selected from —(CH2)n—S(CH2)n, —O(CH2)n—, thiophene, —SO2(CH2)n—, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.

Abstract: This invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, and (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof for manufacturing of a medicinal product or a food stuff for the treatment and/or prevention of amyloidos-related diseases, such as Alzheimer's disease, as well as treatment/prevention of cognitive dysfunction.

Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Abstract: The present invention relates to a vaseline-like composition, comprising one type or two or more types of components selected from the following components (C), (D) and (E) at 5% by weight to 20% by weight, the following component (A) at 40% by weight to 90% by weight, and the following component (B) at 5% by weight to 50% by weight, and to a cosmetic containing the vaseline-like composition: component (A): one or more types of ester compounds selected from diisostearyl malate and diglyceryl triisostearate; component (B): a hydrocarbon wax having a melting point of 70° C. to 130° C.; component (C): a poly(12-hydroxystearic acid) having an average degree of polymerization of 3 to 20; component (D): a poly(12-hydroxystearic acid) derivative obtained by esterifying a poly(12-hydroxystearic acid) having an average degree of polymerization of 3 to 20 and a polyvalent alcohol having a valence of 5 or more; and, component (E): a dimer dilinoleic acid derivative.

Abstract: Provided are novel compositions exhibiting highly effective antiviral, antimicrobial and/or antifungal activity. The compositions of the invention can be used for sanitizing and/or disinfecting surfaces, e.g., inanimate and/or animate surfaces. Preferred compositions include a synergistic combination of an alcohol, docusate, geraniol and, optionally, menthol. The invention provides compositions that have high antimicrobial activity, yet are mild, non-irritating, quick drying, non-sticky and not drying to the skin. Processes for manufacturing and using the compositions and products containing such compositions are also disclosed.

Abstract: The present invention provides oil compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration.

Abstract: The invention relates to the use of triglycerides which an enhanced portion of the palmitic acid residues in the sn-2 position for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.

Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

Abstract: Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.

Abstract: An antibacterial composition includes a combination of fatty acid ester of fatty acid and hydroxy carboxylic acid with an antibacterial agent selected from polylysine, chitosan, protamine, their salts and mixtures hereof. The hydroxy carboxylic acid may be present as acid in its free form, in its salt form and/or in its ester form. The composition may be used as an antibacterial agent against gram-negative bacteria in various products, applications and methods.

Abstract: Nose ointment for the prophylaxis of inhalation allergic reactions comprising at least one mixture of saturated hydrocarbons characterized in that the at least one mixture of saturated hydrocarbons has a viscosity by the DIN 51 562 method of >6 mm2/s (100° C.).

Abstract: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.

Abstract: Provided are compositions and methods for modulating quorum sensing in microbes. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing. The compounds are useful for modulating quorum sensing in bacteria and can be used in methods for prophylaxis or therapy of bacterial infections and for reduction of biofilms.

Abstract: The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil.

Abstract: This invention relates to synergistic combinations of selected microbicides in combination with a second microbicide or formulation ingredient or raw material. The combinations have greater efficacy than would be expected from combinations of the individual components. The combinations include mixtures of (a) 5-Chloro-2-methyl-4-isothiazolin-3-one+2-Methyl-4-isothiazolin-3-one, (b) Methyl-4-isothiazolin-3-one, or (c) 1,2-Benzisothiazolin-3-one with one or more of a variety of other compounds.

Abstract: Compositions and methods of treatment or prophylaxis of fragile-X associated disorders are provided, as well as methods of screening compounds and kits to screen a library of compounds.

Abstract: Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and eicosapentaenoic acid. In some embodiments the omega-3 fatty acid compositions comprise fish oil. In some embodiments the subjects to be treated are receiving parenteral nutrition. In some embodiments the subjects to be treated are infants having a low birth weight, very low birth weight, extremely low birth weight, a low gestational age, short bowel syndrome, necrotizing entercolitis, or any combination thereof.

Abstract: The present invention relates to a cosmetic composition having a high content of a stable oil phase, and more particularly to a cosmetic composition, which combines advantages of spreadability and softness of an oil-in-water type with emollient effect and water resistance of a water-in-oil type as a resulting of stabilizing, based on the total weight of the composition, 30-56 wt % of an oily component by multiple emulsification of W/O/W, and which provides skin moisturizing and softening ef-fects by a large amount of oil components, and also which allows irritations caused by active ingredients to be relieved by a high content of the oily component.

Abstract: Novel compounds, and in particular to diacylglycerol (1,3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases.

Abstract: A softgel of NLKJ for the treatment of prostate diseases, comprising 0.05˜1.0 g of NLKJ and 0.05˜1.5 mg of an antioxidant, said NLKJ having the following physicochemical parameter: acid value<0.56, iodine value 95.0-107.00, saponification value 185.00-195.00, specific gravity 0.914-0.918 (20° C.), and refractive index 1.470-1.475 (20° C.). The inhibition of the softgel of NLKJ on the growth of prostate cancer in combination with the injection of Lupron is stronger than that of each of them used alone.

Abstract: D-aspartic acid is prepared as its hydrochloride salt or as the hydrochloride salt of its diethyl ester, thereby providing soluble forms of D-aspartic acid that are readily taken up by a human body via its digestive tract. The D-aspartic acid is administered as pills, capsules, powdered drink mixes, beverages, confectionaries, syrups, chewable tablets, nasal sprays, or injectable formulations.

Abstract: A composition for topical application to the skin comprises a cocoa polyphenol extract in combination with an SUS-rich fat, wherein the cocoa polyphenol extract is present in an amount of less than 15% by weight based on the weight of the SUS-rich fat, and a cosmetically acceptable carrier. The composition and the extract that it contains may increase skin elasticity and thickness and/or have an anti-wrinkle effect, may cause the depigmentation of age spots, improve skin renewal and/or reduce skin dryness such as reducing discomfort of chapped hands.

Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.